Reevaluating Neonatal Erythromycin Prophylaxis Policy Amid Advances in Sexually Transmitted Infection Screening,...

Area of Science:

• Neonatal Care
• Infectious Disease Prevention
• Public Health Policy

Background:

• Historically, universal ophthalmic prophylaxis with erythromycin was mandated for all neonates in the US.
• This practice aimed to prevent blindness from Neisseria gonorrhoeae (gonococcal ophthalmia neonatorum, GON) and Chlamydia trachomatis (chlamydial ophthalmia neonatorum, CON).
• Prenatal screening and treatment have significantly reduced the incidence of these infections at birth.

Purpose of the Study:

• To analyze contemporary evidence regarding the efficacy and necessity of universal neonatal ophthalmic prophylaxis.
• To evaluate the risks associated with routine erythromycin use in newborns.
• To advocate for evidence-based, risk-stratified prevention models for ophthalmia neonatorum.

Main Methods:

• Integration of current epidemiologic data on neonatal eye infections.
• Review of public health policies and guidelines for ophthalmic prophylaxis.
• Analysis of the benefits versus risks of universal erythromycin administration.

Main Results:

• Gonococcal ophthalmia neonatorum (GON) is exceedingly rare in the United States.
• Erythromycin has demonstrated ineffectiveness in preventing chlamydial ophthalmia neonatorum (CON).
• Concerns exist regarding antimicrobial resistance, medication shortages, and neonatal microbiome disruption.

Conclusions:

• Continuing universal ophthalmic prophylaxis offers minimal clinical benefit and exposes newborns to unnecessary antibiotics.
• The current policy conflicts with modern antibiotic stewardship principles.
• Risk-based prevention models, adopted by many high-income countries, present a safer, evidence-aligned alternative for neonatal eye infection prevention.